Regeneron (REGN) Receives a Hold from Cowen & Co.


Cowen & Co. analyst Yaron Werber maintained a Hold rating on Regeneron (REGN) today and set a price target of $353. The company’s shares opened today at $301.13, close to its 52-week low of $295.73.

According to TipRanks.com, Werber is a 4-star analyst with an average return of 11.6% and a 56.9% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.

The word on The Street in general, suggests a Hold analyst consensus rating for Regeneron with a $380.83 average price target, which is a 26.5% upside from current levels. In a report issued on May 20, Credit Suisse also initiated coverage with a Hold rating on the stock with a $336 price target.

See today’s analyst top recommended stocks >>

Regeneron’s market cap is currently $33.06B and has a P/E ratio of 14.28. The company has a Price to Book ratio of 3.50.

Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts